Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Drug Policy Analysis

A Journal of Substance Abuse Control Policy

Ed. by Kleiman, Mark / Kilmer, Beau


CiteScore 2018: 0.29

SCImago Journal Rank (SJR) 2018: 0.416
Source Normalized Impact per Paper (SNIP) 2018: 0.120

Online
ISSN
1941-2851
See all formats and pricing
More options …

Higher Regulatory Control of Tramadol to Prevent its Abuse and Dependence

Sahba Jalali / Dixon Thomas / Padma Shetty / Jason C. Cooper
Published Online: 2017-08-29 | DOI: https://doi.org/10.1515/jdpa-2016-0008

Abstract

Tramadol abuse potential is not well studied. While some studies claim low abuse potential, others signal significant public health risks associated with tramadol abuse. This is a review on the abuse and dependence potential of tramadol. Tramadol was originally approved as non-controlled drug, but there is a trend to recognize tramadol as a controlled substance by regulators in many countries. Several factors contribute to abuse of tramadol. The leading reasons include history of drug abuse, geographical variation, and lessened regulatory controls. Tramadol abuse can cause increases in seizures and suicidal ideations. Abusers experience withdrawal symptoms and worsening of depression. Higher regulatory control of tramadol is warranted to avoid its misuse.

Keywords: tramadol; controlled substance; abuse; dependence; depression; regulatory control

Highlights

  • Tramadol abuse and dependence are growing global health concerns.

  • Many regulators tightened the control of tramadol in the recent past.

  • History of drug abuse, imperfections in regional healthcare delivery, and lesser regulatory controls are there reasons identified to increase tramadol abuse.

References

  • Abbas, R. A., R. A. Hammam, S. S. El-Gohary, L. M. Sabik, and M. S. Hunter. 2013. “Screening for Common Mental Disorders and Substance Abuse among Temporary Hired Cleaners in Egyptian Governmental Hospitals, Zagazig City, Sharqia Governorate.” The International Journal of Occupational and Environmental Medicine 4 (1):13–26.PubMedGoogle Scholar

  • Adams, E. H., S. Breiner, T. J. Cicero, A. Geller, J. A. Inciardi, S. H. Schnoll, E. C. Senay, and G. E. Woody. 2006. “A Comparison of the Abuse Liability of Tramadol, NSAIDs, and Hydrocodone in Patients with Chronic Pain.” Journal of Pain and Symptom Management 31 (5):465–476.PubMedCrossrefGoogle Scholar

  • Al-Hemiary, N. J., J. K. Al-Diwan, A. L. Hasson, and R. A. Rawson. 2014. “Drug and Alcohol Use in Iraq: Findings of the Inaugural Iraqi Community Epidemiological Workgroup.” Substance Use & Misuse 49 (13):1759–1763.CrossrefWeb of SciencePubMedGoogle Scholar

  • Ardakani, Y. H., R. Mehvar, A. Foroumadi, and M. R. Rouini. 2008. “Enantioselective Determination of Tramadol and Its Main Phase I Metabolites in Human Plasma by High-Performance Liquid Chromatography.” Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 864 (1–2):109–115.CrossrefPubMedGoogle Scholar

  • Bassiony, M. M., G. M. Salah El-Deen, U. Yousef, Y. Raya, M. M. Abdel-Ghani, H. El-Gohari, and S. A. Atwa. 2015. “Adolescent Tramadol Use and Abuse in Egypt.” The American Journal of Drug and Alcohol Abuse 41 (3):206–211.CrossrefWeb of SciencePubMedGoogle Scholar

  • Cicero, T. J., E. H. Adams, A. Geller, J. A. Inciardi, A. Munoz, S. H. Schnoll, et al. 1999. “A Post Marketing Surveillance Program to Monitor Ultram (Tramadol Hydrochloride) Abuse in the United States.” Drug and Alcohol Dependence 57:7–22.CrossrefPubMedGoogle Scholar

  • Cossmann, M., C. Kohnen, R. Langford, and C. McCartney. 1997. “Tolerance and Safety of Tramadol Use. Results of International Studies and Data from Drug Surveillance.” Drugs 53 (Suppl 2):50–62.PubMedGoogle Scholar

  • Dart, R. C., H. L. Surratt, T. J. Cicero, M. W. Parrino, S. G. Severtson, B. Bucher-Bartelson, and J. L. Green. 2015. “Trends in Opioid Analgesic Abuse and Mortality in the United States.” The New England Journal of Medicine 372 (3):241–248.PubMedCrossrefGoogle Scholar

  • Duke, A. N., G. E. Bigelow, R. K. Lanier, and E. C. Strain. 2011. “Discriminative Stimulus Effects of Tramadol in Humans.” Journal of Pharmacology and Experimental Therapeutics 338:255–262.CrossrefWeb of ScienceGoogle Scholar

  • Enabah, D., H. El Baz, and H. Moselhy. 2014. “Higher Frequency of C.3435 of the ABCB1 Gene in Patients with Tramadol Dependence Disorder.” The American Journal of Drug and Alcohol Abuse 40 (4):317–320.PubMedCrossrefWeb of ScienceGoogle Scholar

  • Ferrari, A., I. Tiraferri, F. Palazzoli, and M. Licata. 2014. “Tramadol Abuse in a Binge Pattern in a Young Depressed Woman.” European Addiction Research 20 (2):82–86.Web of ScienceCrossrefGoogle Scholar

  • Häkkinen, M., T. Launiainen, E. Vuori, and I. Ojanperä. 2012. “Comparison of Fatal Poisonings by Prescription Opioids.” Forensic Science International 222 (1–3):327–331.CrossrefWeb of SciencePubMedGoogle Scholar

  • Jovanovic-Cupic, V., Z. Martinovic, and N. Nešic. 2006. “Seizures Associated with Intoxication and Abuse of Tramadol.” Clinical Toxicology 44:143–146.CrossrefGoogle Scholar

  • Khan, N. A., M. A. Sullivan, M. G. Vitale, M. E. Tresgallo, and J. M. Saroyan. 2013. “Undetected Ultracet™ Dependence in an Adolescent with Nonmalignant Back Pain.” Journal of Opioid Management 9 (3):225–230.CrossrefGoogle Scholar

  • Liu, Z. M., W. H. Zhou, Z. Lian, Y. Mu, Z. H. Ren, J. Q. Cao, and Z. J. Cai. 1999. “Drug Dependence and Abuse Potential of Tramadol.” Zhongguo Yao Li Xue Bao 20 (1):52–54.PubMedGoogle Scholar

  • Medscape. FDA Warns of Suicide Risk for Tramadol. Accessed November 07, 2016. http://www.medscape.com/viewarticle/722488.

  • Mehrpour, O. 2013. “Addiction and Seizure Ability of Tramadol in High-Risk Patients.” Indian Journal of Anaesthesia 57 (1):86–87.PubMedCrossrefGoogle Scholar

  • Nazarzadeh, M., Z. Bidel, and K. V. Carson. 2014. “The Association between Tramadol Hydrochloride Misuse and Other Substances Use in an Adolescent Population: Phase I of a Prospective Survey.” Addictive Behaviors 39 (1):333–337.CrossrefWeb of ScienceGoogle Scholar

  • Nordmann, S., V. Pradel, M. Lapeyre-Mestre, E. Frauger, V. Pauly, X. Thirion, M. Mallaret, E. Jouanjus, and J. Micallef. 2013. “Doctor Shopping Reveals Geographical Variations in Opioid Abuse.” Pain Physician 16 (1):89–100.PubMedGoogle Scholar

  • O’Neil, M. G. Trends in Prescription Drug Abuse: ‘Bridging Medications’. Accessed November 07, 2016. http://www.medscape.com/viewarticle/804740.

  • Ojha, R., and S. C. Bhatia. 2010. “Tramadol Dependence in a Patient with No Previous Substance History.” Primary Care Companion to the Journal of Clinical Psychiatry 12 (1):PCC.09100779. doi:.CrossrefGoogle Scholar

  • Randall, C., and J. Crane. 2014. “Tramadol Deaths in Northern Ireland: A Review of Cases from 1996 to 2012.” Journal of Forensic and Legal Medicine 23:32–36.CrossrefPubMedWeb of ScienceGoogle Scholar

  • Reeves, R. R., and V. Liberto. 2001. “Abuse of Combinations of Carisoprodol and Tramadol.” Southern Medical Journal 94:512–514.CrossrefPubMedGoogle Scholar

  • Roussin, A., O. Doazan-d’Ouince, H. Géniaux, and C. Halberer. 2015. “Evaluation of Abuse and Dependence in Addiction Monitoring Systems: Tramadol as an Example.” Therapie 70 (2):203–221.Web of SciencePubMedGoogle Scholar

  • Sarkar, S., N. Nebhinani, and D. Basu. 2012. “Tramadol Dependence: A Case Series from India.” Indian Journal of Psychological Medicine 34 (3):283–285.CrossrefPubMedGoogle Scholar

  • Scheck, J. “Tramadol: The Opioid Crisis for the Rest of the World.” The Wall Street Journal Accessed December 05, 2016. http://www.wsj.com/articles/tramadol-the-opioid-crisis-for-the-rest-of-the-world-1476887401.

  • Senay, E. C., E. H. Adams, A. Geller, J. A. Inciardi, A. Muñoz, S. H. Schnoll, G. E. Woody, and T. J. Cicero. 2003. “Physical Dependence on Ultram (Tramadol Hydrochloride): Both Opioid-Like and Atypical Withdrawal Symptoms Occur.” Drug and Alcohol Dependence 69 (3):233–241.PubMedCrossrefGoogle Scholar

  • Shanna, B., R. Lofwall Michelle, A. Nuzzo Paul, J. Siegel Anthony, and L. Walsh Sharon. 2013. “Abuse Liability and Reinforcing Efficacy of Oral Tramadol in Humans.” Drug and Alcohol Dependence 129 (1–2):116–124.Web of ScienceCrossrefPubMedGoogle Scholar

  • Skipper, G. E., C. Fletcher, R. Rocha-Judd, and D. Brase. 2004. “Tramadol Abuse and Dependence among Physicians.” JAMA 292:1818–1819.PubMedGoogle Scholar

  • Surratt, H. L., C. O’Grady, S. P. Kurtz, Y. Stivers, T. J. Cicero, R. C. Dart, and M. Chen. 2014. “Reductions in Prescription Opioid Diversion following Recent Legislative Interventions in Florida.” Pharmacoepidemiology and Drug Safety 23 (3):314–320.Web of ScienceCrossrefPubMedGoogle Scholar

  • Tjäderborn, M., A. K. Jönsson, J. Ahlner, and S. Hägg. 2009. “Tramadol Dependence: A Survey of Spontaneously Reported Cases in Sweden.” Pharmacoepidemiology and Drug Safety 18:1192–1198.CrossrefPubMedGoogle Scholar

  • WHO Expert Committee on Drug Dependence Thirty-sixth report. Tramadol update review report. WHO technical reports series No.991, 2014. Accessed October 29, 2016. http://www.who.int/medicines/areas/quality_safety/6_1_Update.pdf.

  • Yates, W. R., M. H. Nguyen, and J. K. Warnock. 2001. “Tramadol Dependence with No History of Substance Abuse (Letter).” The American Journal of Psychiatry 158:964.CrossrefPubMedGoogle Scholar

  • Zabihi, E., A. Hoseinzaadeh, M. Emami, M. Mardani, B. Mahmoud, and M. A. Akbar. 2011. “Potential for Tramadol Abuse by Patients Visiting Pharmacies in Northern Iran.” Substance Abuse 5:11–15.Google Scholar

  • Zhang, H., and Z. Liu. 2013. “The Investigation of Tramadol Dependence with No History of Substance Abuse: A Cross-Sectional Survey of Spontaneously Reported Cases in Guangzhou City, China.” BioMed Research International 2013, Article ID 283425, 6 pages. doi:.CrossrefWeb of ScienceGoogle Scholar

About the article

Published Online: 2017-08-29


Citation Information: Journal of Drug Policy Analysis, Volume 10, Issue 2, 20160008, ISSN (Online) 1941-2851, ISSN (Print) 2194-6337, DOI: https://doi.org/10.1515/jdpa-2016-0008.

Export Citation

© 2017 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in